A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Study Summary

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions / Drugs

Amivantamab Osimertinib Lazertinib Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment1074 participants

Primary Completion—

Lead SponsorJanssen Research & Development, LLC

Data Retrieved2026-04-11 02:55:31.551088+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.